Friday November 27 2009 | Biotechnology feed | All feeds

BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

BioPortfolio's Approved Drugs Database

Femcon

Ethinyl Estradiol Norethindrone

Download PDF containing detailed information.PDF Version

Image Results

Loading...

Press Releases About Femcon:

 BioPortfolio Logo
Warner Chilcott and Watson Pharmaceuticals Announce Agreements on Loestrin(R) 24 and Femcon(R) Fe Patent Litigation 12th January, 2009 Watson Pharmaceuticals, Inc.
HAMILTON, Bermuda and CORONA, Calif., Jan. 12 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) and Warner Chilcott Limited (Nasdaq: WCRX) announced today that they have entered
Warner Chilcott and Barr Announce Settlement of Femcon(R) Fe Patent Challenge 22nd December, 2008 Warner Chilcott Limited
ST. DAVID'S, Bermuda, Dec. 22 /PRNewswire-FirstCall/ -- Warner Chilcott Limited (Nasdaq: WCRX) today announced that its subsidiary Warner Chilcott Company, Inc. and Barr Laboratories, Inc., a

This page has been viewed 35 times Browse BioPortfolio's InDepth service - alphabetically: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z or by Most Publications, recently searched for, or most viewed.

Search for Femcon across BioPortfolio, or for Femcon Research Reports
Wikipedia excerpt, where present, licenced under the GNU Free Documentation License. Resources from the NCBI applied. Selected MeSH subject headings created and maintained by the US NLM are used in conjunction with additional keywords. 2006-2008 MeSH. Thumbshots from Thumbshots.org

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.